Enasidenib-Induced Differentiation Syndrome in IDH2-Mutant Acute Myeloid Leukemia

被引：5
|
作者：
Patel, Shyam A. [1 ,2 ]
机构：
[1] Stanford Univ, Dept Med, Div Hematol, Stanford Canc Inst,Sch Med, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Med, Div Oncol, Stanford Canc Inst,Sch Med, Stanford, CA 94305 USA
来源：
JAMA ONCOLOGY | 2018年 / 4卷 / 08期
关键词：
MUTATIONS;
D O I：
10.1001/jamaoncol.2017.4724
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1110 / +
页数：3
相关论文
共 50 条
  • [31] NPMC COOPERATES WITH MUTANT IDH2 TO INDUCE ACUTE MYELOID LEUKEMIA
    Ogawara, Yoko
    Katsumoto, Takuo
    Aikawa, Yukiko
    Kagiyama, Yuki
    Kitabayashi, Issay
    EXPERIMENTAL HEMATOLOGY, 2013, 41 (08) : S55 - S55
  • [32] Combination of Menin and IDH Mutant Inhibition in Acute Myeloid Leukemia
    Yoon, James J.
    Miao, Hongzhi
    Purohit, Trupta
    Chen, Dong
    Cierpicki, Tomasz
    Grembecka, Jolanta
    BLOOD, 2022, 140 : 5946 - 5946
  • [33] Dermatologic adverse events in acute myeloid leukemia patients treated with IDH inhibitors ivosidenib and enasidenib
    Parisi, Rose
    Stoll, Joseph
    Zhu, Haoling
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB38 - AB38
  • [34] The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
    Nassereddine, Samah
    Lap, Coen J.
    Haroun, Faysal
    Tabbara, Imad
    ANNALS OF HEMATOLOGY, 2017, 96 (12) : 1983 - 1991
  • [35] The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
    Samah Nassereddine
    Coen J. Lap
    Faysal Haroun
    Imad Tabbara
    Annals of Hematology, 2017, 96 : 1983 - 1991
  • [36] Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia
    Parisi, Rose
    Cowen, Emily A.
    Stoll, Joseph R.
    Zhu, Haoling
    Dusza, Stephen
    Pulitzer, Melissa P.
    Stein, Eytan M.
    Markova, Alina
    LEUKEMIA RESEARCH, 2022, 123
  • [37] AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo
    Shih, Alan H.
    Shank, Kaitlyn R.
    Meydan, Cem
    Intlekofer, Andrew M.
    Ward, Patrick
    Thompson, Craig B.
    Melnick, Ari M.
    Travins, Jeremy
    Straley, Kim
    Gliser, Camelia
    Yen, Katherine
    Levine, Ross L.
    BLOOD, 2014, 124 (21)
  • [38] Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
    Amatangelo, Michael D.
    Quek, Lynn
    Shih, Alan
    Stein, Eytan M.
    Roshal, Mikhail
    David, Muriel D.
    Marteyn, Benoit
    Farnoud, Noushin Rahnamay
    de Botton, Stephane
    Bernard, Olivier A.
    Wu, Bin
    Yen, Katharine E.
    Tallman, Martin S.
    Papaemmanuil, Elli
    Penard-Lacronique, Virginie
    Thakurta, Anjan
    Vyas, Paresh
    Levine, Ross L.
    BLOOD, 2017, 130 (06) : 732 - 741
  • [39] IDH Inhibitors in Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Stein, Eytan M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 556 - 558
  • [40] An evaluation of enasidenib for the treatment of acute myeloid leukemia
    Del Principe, Maria Ilaria
    Paterno, Giovangiacinto
    Palmieri, Raffaele
    Maurillo, Luca
    Buccisano, Francesco
    Venditti, Adriano
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (16) : 1935 - 1942
12345